Inflammation is paradoxical; it is essential for protection following biological,
Inflammation: a role for NR4A orphan nuclear receptors?
acute inflammation, the endothelium is activated, resulting in the release of cytokines and enhanced expression of cellsurface adhesion molecules, which facilitate the attraction of immune cells, including leucocytes and monocytes, to the site of inflammation. Following inflammatory resolution, the endothelium reverts to a quiescent normal state.
Chronic joint inflammation causes a state of continued endothelial cell activation, resulting in perpetuation of the inflammatory environment and immune cell recruitment [3] [4] [5] [6] [7] . In addition to the pro-inflammatory mediators secreted by the activated endothelium, macrophage-derived cytokines are potent mitogens for proliferating FLSs (fibroblast-like synoviocytes) in the vicinity of the affected cartilage that produce matrix-degrading molecules. FLSs and macrophages within the synovium orchestrate a selfperpetuating inflammatory response via the autocrine actions of cytokines [e.g. TNFα (tumour necrosis factor α), IL (interleukin) -1β], growth factors [e.g. bFGF (basic fibroblast growth factor) and VEGF (vascular endothelial growth factor)] and prostaglandins [e.g. PGE 2 (prostaglandin E 2 )] [4, 6, 7] . It is the persistent, invasive and destructive growth of synovial tissue that ultimately leads to joint erosion [7, 8] . The long-term prognosis for RA sufferers is poor, with 80% of affected patients presenting with significant joint damage and functional disability after 20 years. Life expectancy for these patients is strikingly reduced by an average of 3-18 years [9] . This increased mortality is predominantly associated with accelerated coronary artery disease and cerebrovascular atherosclerosis [9] .
Ps (psoriasis), like RA, is an autoimmune disorder, with chronic dermatosis, which is also associated with significant morbidity [10] [11] [12] . Ps is characterized by accumulation of erythematous, scaly plaques, with characteristic histological changes of epidermal hyperplasia, inflammatory cell infiltrate and increased vascularity [10] . Increased production and release of cytokines and growth factors by activated Tlymphocytes and macrophage cells trigger basal stem cell keratinocyte proliferation, abnormal terminal differentiation and resistance to apoptotic signals [11, 12] . These inflammatory mediators also support vascular changes and promote angiogenesis, which is a prominent and early event [13, 14] . Over 2% of the population are affected by these disorders and approximately 15% of patients with Ps also develop a sero-negative polyarthritis-PsA [13] .
Atherosclerosis is a chronic inflammatory condition that develops from de-regulation of the immune system and metabolic pathways [15] [16] [17] . As observed in RA, PsA and Ps, the vascular endothelium plays a paramount role in the initiation and development of atherosclerosis, facilitating immune cell ingress leading to increased production of proinflammatory cytokines. Macrophages have been identified as a critical cell type involved in the initiation, progression and rupture of atherosclerotic lesions. Ingestion of modified lipid particles transforms these macrophages into 'foam cells', resulting in the formation of a fatty streak on the vessel wall. These lipid-laden macrophages produce excess amounts of pro-inflammatory molecules and matrix-degrading enzymes, which perpetuate a continued state of chronic inflammation. Over time the number of foam cells increases and the lesion becomes unstable, finally cumulating in the rupture of the lesion [15] .
Regulation of inflammation: NR4A subfamily
Extensive in vitro and in vivo studies have identified a critical role of cytokines and growth factors, as well as the participating cell types, that promote chronic inflammation [6, 7] . What remains to be further explored is the control of transcriptional mediators downstream of these pro-inflammatory signals within these cell systems. Identifying these transcription factors and their co-regulatory proteins (co-activators and co-repressors) will facilitate the development of targeted and specific therapeutic approaches. The NR (nuclear receptor) superfamily has been proposed as key transcription factors capable of modulating both immune and metabolic pathways. Two subgroups within this superfamily, the NR1C/PPAR (peroxisome-proliferator-activated receptor) and NR1H/LXR (liver X receptor) receptors, have been identified as important transcriptional modulators of both inflammation and lipid homoeostasis [16, 17] .
Recent interest has focused on the NR4A subfamily of orphan NRs. The NR4A (NR4A1/NUR77, NR4A2/NURR1 and NR4A3/NOR1) subfamily has emerged as potential regulators of cytokine and growth factor action through regulating the inflammatory response underlying several diseases. NR4A transcription factors are aberrantly expressed in inflamed human synovial tissue, colorectal cancer cells, Ps, atherosclerotic lesions and multiple sclerosis [18] [19] [20] [21] [22] [23] [24] [25] . In activated primary cells, NR4A receptors are rapidly and potently induced by a range of cytokines, suggesting that these receptors act as potential transcriptional mediators of inflammatory signals [19, [26] [27] [28] . The transcriptional function of these receptors in response to inflammatory molecules is under intense investigation, and several NR4A target genes have recently been identified [21] [22] [23] [24] [25] [26] [27] [28] .
Modulation of inflammation: disease-modifying drugs
While NR4A activity does not appear to be regulated by endogenous ligands, pharmacological modulation of NR4A activity can be achieved with the antineoplastic agent 6-mercaptopurine [29] . In addition, altering expression, subcellular localization or post-translational modification of these receptors may be a feasible approach to modulate NR4A activity and target gene expression. Dexamethasone and MTX (methotrexate), used in the treatment of joint and skin diseases, can regulate NR4A2 expression in vitro and in vivo [26, 30] (Figure 1 ). These studies suggest that the clinical benefits of these agents may be mediated through altered NR4A2 expression and activity.
Traditionally, therapies for chronic inflammation with non-specific disease-modifying medications, including MTX, have been limited by both inefficacy and the development of adverse drug reactions in patients [31, 32] . MTX significantly reduces cellular infiltration via decreased expression of cell-surface adhesion molecules reducing the levels of soluble mediators of inflammation such as MMPs (matrix metalloproteinases) and cytokines [33, 34] . Several lines of evidence now indicate that the immunosuppressive and antiinflammatory actions of low dose MTX are not due to inhibition of folate metabolism and are mediated by its capacity to increase extracellular adenosine levels [35] . The molecular targets modulated by MTX and adenosine are being revealed through the creation and appropriate study of in vivo models of acute and chronic inflammation [36, 37] .
The importance of the adenosine A 2A receptor in mediating inflammatory resolution and wound healing is clearly demonstrated in the adenosine A 2A − / − receptor mice [38] . Promotion of angiogenesis is an integral component in the mechanism of repair and is necessary for the transport of oxygen, nutrients and inflammatory cells to promote healing. Interestingly, adenosine, acting at one or more of the four adenosine membrane receptors, may regulate angiogenesis through tilting the dynamic balance of angiogenic mediators. Acting through the A 2A receptor, adenosine stimulates endothelial cell migration and proliferation in vitro and increases secretion of the pro-angiogenic VEGF, while down-regulating the angiostatic matricellular protein thrombospondin [36, 39] . In addition, adenosine regulates inflammation in cell types important for the repair of tissue damage, such as neutrophils, macrophages, endothelial cells and lymphocytes (Figure 2 ). Cronstein and co-workers have demonstrated that the A 2A receptor is required for uniform formation of granulation tissue and revascularization in a model of wound repair [37] .
The cell-specific signal transduction events and the transcriptional mediators that act to promote adenosine receptor-mediated responses during acute inflammation and tissue repair are largely unknown. Findings from our laboratory establish NR4A2 as a molecular target of MTX action in human inflammatory joint disease and demonstrate that the immunomodulatory actions of MTX on NR4A2 expression are mediated through adenosine release and A 2A receptor modulation [30] . Significantly, the role of NR4A receptors in inflammatory resolution, wound repair or healing remains to be uncovered.
Cytokine blockade
The success of treating inflammatory joint and skin disease with non-specific disease-modifying drugs has been limited by both inefficacy and the development of adverse drug reactions in up to 50% of patients [31, 32] . In recent years, targeted therapy with biological agents, which are highly specific and directed against pro-inflammatory molecules, such as TNF, has been shown to be highly efficacious in the treatment of Ps, PsA and RA [4, 6, 7, 14, 20] . Currently, the early treatment of joint and skin disease with anti-TNF agents alone, as well as combination therapies involving MTX, is a therapeutic approach under intense investigation [40] [41] [42] . Clinical results indicate that the early administration of such drug combinations may induce a sustained remission in up to 20% of patients. Thus the blockade of TNFα provides an important benchmark for the continued development of new therapies to treat chronic inflammatory conditions [7] . A more detailed understanding of the mediators that drive distinct stages of inflammatory disease may reveal biomarkers for the quantitative assessment of diagnosis and facilitate the introduction of appropriate and effective treatment(s) early in disease. Such studies may also provide new opportunities for the development of therapeutics to target specific mediators central to distinct phases of chronic inflammatory disease.
Given that the transcriptional function of NR4A receptors can be controlled at the level of expression and nuclear localization, we recently examined the expression of NR4A2 in Ps skin and monitored the biological effects on this receptor following inhibition of TNFα signalling [20] . Increased expression levels of NR4A2 mRNA and protein are present in involved Ps skin compared with uninvolved and normal skin, which correlates significantly with clinical measures of the Ps area and severity index [20] . Enhanced NR4A2 expression localizes to both the nucleus and the cytoplasm of cells of involved epidermis, blood vessels and inflammatory infiltrates, in contrast with predominant cytoplasmic distribution in uninvolved and normal skin. Importantly, following TNFα inhibition with infliximab or etanercept, NR4A2 expression in involved skin was significantly decreased and cytoplasmic distribution was restored [20] .
Target genes and physiological functions of NR4A receptors are likely to be tissue-and context-dependent. Recent findings reveal that OA (osteoarthritis) joint tissues produce markedly increased levels of NR4A receptors compared with normal tissue [30, 43] . In OA cartilage, relative to other family members NR4A1 and NR4A3, NR4A2 is expressed at the highest level. Consistent with advanced cartilage degradation and inflammation, COX-2 (cyclo-oxygenase-2) levels are also significantly elevated and correlate with changes in NR4A2 gene expression. Interestingly, it has been demonstrated that COX-2-derived PGE 2 can rapidly and potently induce NR4A2 levels in primary human chondrocytes and cancer cells [19, 43] . Furthermore, enhanced NR4A2 activity leads to elevated transcriptional repression of MMP gene expression in chondrocyte cells [43] .
Cells that promote chronic inflammation: macrophage cells
Several cell types including mast cells, fibroblasts, neutrophils, T-and B-lymphocytes have been implicated in the initiation and progression of chronic inflammatory conditions. It is now emerging that a central cell player in Regulation of the inflammatory response is controlled by alternatively activated macrophage cells with classically M1 macrophages producing a wide variety of pro-inflammatory mediators. In contrast, alternatively activated M2 macrophages participate in anti-inflammatory response and promote tissue repair. Adenosine A 2A receptors regulate the processes involved in wound healing, including the transition of macrophages to the M2 phase [34] [35] [36] [37] [38] [39] . The mechanism of switching macrophages to an M2 phenotype may be a prerequisite for resolution of inflammation. Tissue repair is characterized by three overlapping phases: inflammation, tissue formation and tissue remodelling. Models of acute and chronic inflammation will permit the contribution and physiological functions of NR4A receptors during the initiation and resolution phases of inflammation to be examined. EC, endothelial cell; TLR, Toll-like receptor; TSP1, thrombospondin 1.
this process are cells of the monocyte/macrophage lineage. Macrophages orchestrate host defence by recognizing and destroying foreign organisms, produce cytokines, growth factors and angiogenic mediators that regulate inflammation, angiogenesis and granulation tissue formation [2, 7] . The involvement of macrophages in the initiation of diseases, such as RA, has been supported by the observed increase in macrophage cell numbers in the synovial lining and sublining layer of inflamed joints [44] . Following effective treatment using TNF blockade, a significant reduction in macrophage cell number in the synovial lining layer has been recorded; however, the exact mechanisms of this response are unclear [44] . These observations propose that changes in macrophage cell numbers may be measured as biomarkers for successful therapeutic treatment and used as an indicator of patients' response to drug therapy.
The involvement of NR4A receptors in mediating proinflammatory signalling has been demonstrated by Pei et al. [25] in murine macrophage cells via activation of the NF-κB (nuclear factor κB) pathway. Ectopic expression of NR4A1, using retroviral gene transduction, increases the expression of NF-κB-activating kinases, IKKi [IκB (inhibitor of NF-κB) kinase i] and NIK (Nck-interacting kinase; also known as NF-κB-inducing kinase) and identifies IKKi as a direct target of NR4A1 transcriptional activity [25, 27] . In addition, functional studies demonstrate both pro-and anti-inflammatory roles for NR4A1, suggesting that acute or chronic expression levels of these receptors in distinct cell types may permit differential effects on gene expression [18, 25, 27, 45] . NR4A receptors may act as anti-inflammatory modulators in an in vitro model of human THP-1 macrophage cells [21] . In this study, NR4A overexpression led to a reduction in the synthesis of several cytokines and chemokines with reduced oxidized LDL (lowdensity lipoprotein) uptake by THP-1-derived macrophages. Consistent with these findings, another recent study also identifies NR4A receptors as effector molecules that attenuate cytokine signalling in microglial cells [46] .
Macrophage polarization: a role for NR4A receptors?
The critical contribution of macrophage cells in mediating the transition from an acute to a chronic state of inflammation in RA has been proposed recently [44] . Macrophage cell populations are more complex than initially thought, and there are reports demonstrating the extent of heterogeneity and plasticity within this cell type [47, 48] and promote inflammatory resolution and tissue repair. Unlike T-or B-lymphocytes, macrophages display a high degree of plasticity, which offers the possibility of 'switching' pro-inflammatory M1 subtype to pro-resolution M2 subtype cells. Altering the macrophage polarization subtype using GM-CSF (granulocyte/macrophage colonystimulating factor) or anti-GM-CSF antibody blockade may offer an exciting possibility of interfering and redirecting the inflammatory response, opening a new avenue of therapeutic intervention [49] . The role of NR4A receptors as transcriptional regulators during macrophage phenotypic differentiation is currently unknown and remains to be explored ( Figure 2 ). It is possible that the polarization status of macrophage cells could predetermine the role NR4A receptors play in regulating and integrating the inflammatory response.
Future directions
Polarization and priming of immune cells are of significant importance in determining the course of the inflammatory response and outcome. The critical role of cytokines, such as IL-33 (recently implicated in mast cell activation), has shed new light on our understanding of the early events that determine the pathophysiology of inflammation [50] . These studies, together with the recent identification of T h 17 and T h 22 T-cell responses, raise compelling questions regarding the regulatory processes controlling the progression from acute to chronic inflammation. This new information is now challenging us to rethink our understanding of the molecular mechanisms underpinning chronic inflammatory disease. 
